Shots:

• With the acquisition of Loxo by Eli Lilly- Bayer exercises its option and get exclusive WW rights to develop and commercialize Vitrakvi and BAY 2731954 including in the US. Loxo to receive royalties on sales of product (Ex-the US)
• Acc to Nov-2017 deal Bayer- and Loxo collaborated to jointly develop and commercialize larotrectinib and BAY 2731954 (LOXO-195) in the US with equal cost and profit sharing
• Vitrakvi (larotrectinib) is an oral TRK inhibitor developed in collaboration with Bayer- targeted for solid tumors with NTRK gene fusion in adult and pediatric patients and has received FDA approval in Nov- 2018. BAY 2731954 (LOXO-195) is an oral drug evaluated in P-I/II for TRK fusion cancers that are resistant to initial TRK therapy

| Ref: Bayer | Image: Bayer